{
  "id": 161166,
  "title": "Dr Agarwal shares jump 5.5%, MS & Jefferies lift target prices after Q1",
  "url": "https://urgent.news/2026/08/05/dr-agarwal-shares-jump-5-5-ms-jefferies-lift-target-prices-after-q1",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-05T05:21:36.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/stock-markets/dr-agarwals-health-care-shares-jump-55-morgan-stanley-amp-jefferies-lift-target-prices-after-strong-q1/article71308175.ece"
  },
  "original_language": "en",
  "account": "Dr Agarwal's shares in the healthcare sector increased by 5.5% on Wednesday following the company's impressive first-quarter results for FY27. The stock's value on the NSE rose to ₹515.80, marking an intraday high of ₹520.90, surpassing the prior close of ₹493.50. The company's profit after tax surged 44.6% to ₹55 crore, outperforming revenue growth despite higher greenfield investments. Revenue from operations expanded 26% year-over-year to ₹614 crore. EBITDA increased by 25.2% to ₹177 crore, maintaining a robust margin of 28.5%. This quarter also saw the largest-ever expansion of new eye care centers. Morgan Stanley upgraded its rating to 'overweight' and set a new target price of ₹576 from ₹555, praising the company's impressive growth, including a 26% YoY revenue increase and 16% same-store sales growth. They anticipate normalization of same-store sales growth and highlight premiumization-led growth, untapped market opportunities, expansion potential, and improved return on capital employed. Jefferies also maintained an 'accumulate' rating and raised its target price to ₹600 from ₹510, commending the company's consistent performance in the June quarter and robust expansion across all regions. They expect mid-teens volume growth and continued premiumization, with same-store sales growth remaining robust.",
  "summary": "Profit after tax surged 44.6% to ₹55 crore, outpacing revenue growth even as the company absorbed higher greenfield investments",
  "key_points": [
    "Dr Agarwal's shares rose 5.5% after Q1 results",
    "MS upgraded rating to 'overweight', target ₹576",
    "Jefferies raised target to ₹600, praised growth"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}